SCHEMBL1503198

SCHEMBL1503198

NC(=O)c1c(Cc2ccc(F)c(Cl)c2)nc(C(=O)NO)c(O)c1CO

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 4/20 0.41
HDAC6 Q9UBN7 2/20 0.41
HDAC3 O15379 1/20 0.41
HDAC2 Q92769 1/20 0.41
IDO1 P14902 1/20 0.39
EGFR P00533 5/20 0.37
PIK3CA P42336 1/20 0.35
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
GPR52 Q9Y2T5 1/20 0.33
PARP1 P09874 2/20 0.33
SCD O00767 1/20 0.33
HDAC7 Q8WUI4 1/20 0.33
SLC6A2 P23975 1/20 0.32
SLC6A4 P31645 1/20 0.32
SLC6A3 Q01959 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2217116 0.91 FYN (0.34) HDAC1HDAC6IDO1GPR52PARP1
SCHEMBL2219513 0.79 IGFBP3 (0.42) HDAC1HDAC6HDAC3HDAC2
SCHEMBL29829563 0.71 HDAC1 (0.52) HDAC1HDAC6HDAC3HDAC2IDO1
SCHEMBL1503191 0.71 HDAC1 (0.52) HDAC1HDAC6HDAC3HDAC2IDO1
SCHEMBL1503109 0.71 HDAC1 (0.47) HDAC1HDAC6HDAC3HDAC2IDO1
SCHEMBL24065372 0.71 HDAC1 (0.52) HDAC1HDAC6HDAC3HDAC2IDO1
SCHEMBL1503063 0.67 GPR52 (0.43) HDAC1HDAC6HDAC3HDAC2EGFR
SCHEMBL2146943 0.66 HDAC3 (0.41) HDAC1HDAC6HDAC3HDAC2IDO1
SCHEMBL2146973 0.66 HDAC3 (0.41) HDAC1HDAC6HDAC3HDAC2IDO1
SCHEMBL2146946 0.66 HDAC3 (0.41) HDAC1HDAC6HDAC3HDAC2IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8742123-B2 HIV integrase inhibitors from pyridoxine TAIMED BIOLOGICS, INC. (TW) 2014-06-03 US claimed
US-20110178120-A1 HIV INTEGRASE INHIBITORS FROM PYRIDOXINE AMBRILIA BIOPHARMA, INC. (CA) 2011-07-21 US claimed
US-8742123-B2 HIV integrase inhibitors from pyridoxine TAIMED BIOLOGICS, INC. (TW) 2014-06-03 US disclosed
US-20110178120-A1 HIV INTEGRASE INHIBITORS FROM PYRIDOXINE AMBRILIA BIOPHARMA, INC. (CA) 2011-07-21 US disclosed
EP-2300433-A1 HIV INTEGRASE INHIBITORS FROM PYRIDOXINE Ambrilia Biopharma Inc. (CA) 2011-03-30 EP disclosed
WO-2009146555-A1 HIV INTEGRASE INHIBITORS FROM PYRIDOXINE AMBRILIA BIOPHARMA INC. (CA) 2009-12-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178120-A1 HIV INTEGRASE INHIBITORS FROM PYRIDOXINE PNPO, CCNB1, BLVRB HDAC1 2694/4885HDAC6 4827/4885HDAC3 4086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.